Life sciences briefing: Tuesday, Oct. 30, 2007
Featured companies: Acceleron Pharma, Bledsoe Brace Systems, Eurobiobiz, Genoptix, Harmony Information Systems, ImmuneWorks, Pasteuria Bioscience, Renal CarePartners, Quantum Genomics, Synergy Software, Vitreo Retinal Technology
UPDATED: Expanded items on Genoptix and Acceleron Pharma.
Diagnostics biotech Genoptix prices IPO above range, raises up to $98M — Genoptix became one of the first biotechs in a long time to demonstrate some oomph with an IPO, pricing its shares above its expected range and then soaring nearly 50 percent in its first day… Continue Reading
IPO roundup: Bioheart, Merrion Pharma in limbo; Reliant vs. Reliant road shows; upcoming offerings
Bioheart’s IPO-related chest pains continue — The week of Oct. 22 has come and gone, and there’s no sign of the scheduled — and already battered — IPO of Bioheart, the Florida company that hopes to treat damaged hearts with patients’ own muscle stem cells. IPO Home now lists the IPO as scheduled on a “day-to-day” basis.
So the jury is still out as to whether the company’s recent halving of its IPO terms will still… Continue Reading
Life sciences briefing: Tuesday, Oct. 9, 2007
Featured companies: AngioScore, Forsight Labs, Genoptix, Metastatix, Optherion, QLT
UPDATED: See below.
Artery opener AngioScore pulls in $30M — AngioScore, a Fremont, Calif., maker of balloon catheters used to open up clogged arteries, raised $30 million in a fifth funding round. Investors included Telegraph Hill Partners, Psilos Group Management, QuestMark Partners, L.P., UV Partners, California Technology Ventures and Innomed Ventures.
AngioScore’s balloon catheters, which inflate inside blocked blood vessels to restore blood flow, are designed to overcome problems that sometimes… Continue Reading
Genoptix files $86M IPO for diagnostic services
Genoptix, a Carlsbad, Calif., provider of diagnostic services to cancer and blood-disease specialists, filed to raise as much as $86.25 million in an intial offering. The company specializes in genetic and other testing of blood and bone-marrow samples in order to diagnose various cancers and to determine appropriate treatments.
Genoptix, it turns out, is another biotech chameleon. Until late 2004, the company was focused on developing laser and optical tools for cellular analysis. Then Genoptix switched… Continue Reading